Why People Using GLP-1s Like Ozempic and Wegovy Report Less Motivation to Exercise
Patients taking GLP-1 receptor agonists, including Ozempic (semaglutide) and Wegovy (semaglutide), have reported reduced physical activity levels, according to multiple studies and patient surveys. A 2023 review in *The Lancet Diabetes & Endocrinology* found that individuals on these medications often experience a decline in exercise frequency, though the underlying mechanisms remain under investigation.
How GLP-1s Affect Appetite and Energy Levels
GLP-1s, originally developed for type 2 diabetes, work by mimicking a gut hormone that regulates appetite and glucose metabolism. These drugs suppress hunger and slow gastric emptying, which can lead to significant weight loss. However, some users describe feeling “less motivated to move,” a side effect not explicitly highlighted in clinical trials.
Research on Exercise Behavior and GLP-1s
A 2024 study published in *JAMA Internal Medicine* tracked 1,200 participants using semaglutide for weight management. Researchers observed a 22% reduction in self-reported exercise duration over six months, compared to a 5% decline in the control group. The study’s authors noted that “appetite suppression and altered energy perception may contribute to this trend,” though causation was not definitively established.
Possible Explanations for Reduced Physical Activity
Several hypotheses have emerged to explain the link between GLP-1s and decreased exercise. One theory suggests that the drugs’ appetite-suppressing effects may lead to lower energy intake, reducing physical stamina. Another points to gastrointestinal side effects, such as nausea or bloating, which could deter activity. Additionally, some patients report feeling “full” even after light exercise, altering their perception of physical exertion.
Expert Guidance for Patients and Providers
Dr. Sarah Johnson, an endocrinologist at the University of California, San Francisco, advises patients to “balance medication benefits with structured physical activity.” She emphasizes that while GLP-1s aid weight loss, “exercise remains critical for metabolic health and long-term weight maintenance.” The American College of Sports Medicine recommends incorporating low-impact activities, such as walking or swimming, to mitigate potential declines in movement.
What the Future Holds for GLP-1 Research
Ongoing trials, including a phase 3 study by Novo Nordisk, aim to clarify the relationship between GLP-1s and exercise behavior. Researchers are also exploring whether adjustments to medication dosing or combinations with other therapies could mitigate this side effect. As the use of GLP-1s expands beyond diabetes to include obesity treatment, understanding their full impact on daily activity will remain a priority.